Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 12/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577109 | 0.85 | TNF (0.44) | TNFKAT2BALDH1A1KDM4EGAA | |
| SCHEMBL5237237 | 0.84 | TNF (0.38) | TNFKAT2BALDH1A1GAAPOLB | |
| SCHEMBL6108164 | 0.81 | CRHBP (0.33) | CRHBPCRHR2ALDH1A1GAAPOLB | |
| SCHEMBL5576641 | 0.81 | GABRA1 (0.36) | CRHBPCRHR2ALDH1A1GAAPOLB | |
| SCHEMBL5237473 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAPOLBNPSR1 | |
| SCHEMBL5238633 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAPOLBNPSR1 | |
| SCHEMBL5236340 | 0.76 | ALDH1A1 (0.40) | ALDH1A1KDM4EGAANPSR1 | |
| SCHEMBL5236351 | 0.73 | BAZ2B (0.45) | ALDH1A1KDM4EGAA | |
| SCHEMBL5236533 | 0.73 | ALDH1A1 (0.41) | TNFALDH1A1KDM4EGAA | |
| SCHEMBL6106729 | 0.72 | TNF (0.41) | TNFKAT2BALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | TNF 4760/4885KAT2B 2602/4885CRHBP 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.